Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are classified as thiopurine drugs and are integral in treating a range of medical conditions, including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and immunosuppression following solid organ transplants. The metabolism of these drugs involves the activity of thiopurine methyltransferase (TPMT), which, due to genetic polymorphism, may exhibit varying enzymatic activity—either null or reduced. Notably, among the identified polymorphisms, TPMT *2, *3A, *3B, *3C, and *4 have been extensively studied. These genetic variations are associated with an increased risk of myelosuppression, a condition marked by reduced blood cell production. In the realm of diagnostics, TPMT genotyping assumes a critical role, providing valuable insights for predicting the susceptibility to myelosuppression linked with thiopurine drug therapy. By pinpointing specific TPMT polymorphisms, Hypro Diagnostics aims to facilitate tailored treatment plans, optimizing drug efficacy while minimizing potential adverse effects. This approach underscores the commitment to precision diagnostics, ensuring safer and more effective thiopurine-based treatments across diverse medical scenarios.
Reviews
There are no reviews yet.